Trial Profile
Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 May 2019
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 03 Jun 2016 Status changed from active, no longer recruiting to completed.
- 04 Sep 2014 Planned End Date changed from 1 Jun 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 18 Feb 2014 According to ther ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Jun 2014.